Cardiol Therapeutics Inc. Quality Score
CRDL
Weak across most dimensions. This doesn't mean avoid, but the burden of proof is on the bull case.
Broad-market heuristics · Not a buy/sell signal
Valuation and growth
Valuation
Growth
Negative earnings, no valuation support
Negative FCF, no valuation support
FCF negative, burning cash after capex
Business Quality & Capital Allocation
Heavy dilution above 5%
Net cash position, no leverage concern
Below 8%, may not cover cost of capital
Cardiol Therapeutics (CRDL) quality: score, margins and returns
Cardiol Therapeutics (CRDL) scores 10/100 on Intrinsiqq's quality score (a lower-quality business), a weighted blend of 4 metrics each scored 0 to 100 and -126.4% ROIC. Every metric is computed from company filings; this is analysis, not investment advice.
Frequently asked
Is Cardiol Therapeutics (CRDL) a high-quality business?+
Cardiol Therapeutics scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which rates it a lower-quality business on these measures. Recent figures include a -126.4% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.
What does Cardiol Therapeutics's quality score measure?+
Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from CRDL's company filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Cardiol Therapeutics scores well and where it falls behind.
What is Cardiol Therapeutics's return on invested capital (ROIC)?+
Cardiol Therapeutics earns about -126.4% on its invested capital, which is weak. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to CRDL's margins and growth on this scorecard to judge durability.
Peers
Drug Manufacturers - Specialty & Generic · Pick stocks to compare with CRDL
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing CRDL
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.